Instinct Bio Technical Company Holdings Inc. received notifications from Nasdaq on September 9 and 10, 2026, indicating non-compliance with three continued listing requirements for the Nasdaq Global Market. The company failed to maintain a minimum market value of listed securities (MVLS) of $50 million, a minimum market value of publicly held shares (MVPHS) of $15 million, and a minimum bid price of $1.00 per share during periods ending in early September 2026. Nasdaq granted the company an 180-day compliance period until March 8 or 9, 2027, to regain compliance by meeting these thresholds for ten consecutive business days. Failure to comply may result in delisting proceedings, though the company may appeal or transfer to the Nasdaq Capital Market. The company is evaluating options to cure these deficiencies and has no guarantee of success. Instinct Bio Technical Company Holdings Inc. operates in the biotechnology industry, focusing on regenerative medicine, wellness technologies, and therapeutic platform development.
